SCHEMBL5120197

SCHEMBL5120197

CC(=O)Nc1cc(C#N)cc(COc2c(Br)cc(C(=O)NCC(=O)O)cc2Br)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 5/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
DHODH Q02127 2/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
THRA P10827 2/20 0.36
THRB P10828 2/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
USP2 O75604 1/20 0.36
SENP5 Q96HI0 1/20 0.36
SENP2 Q9HC62 1/20 0.36
SENP1 Q9P0U3 1/20 0.36
SOST Q9BQB4 1/20 0.35
ITGB3 P05106 1/20 0.35
ITGA2B P08514 1/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
FLT1 P17948 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5110808 0.90 SMN1; SMN2 (0.38) EGLN1MEN1KMT2ASMN1; SMN2DHODH
SCHEMBL5110614 0.90 MRGPRX4 (0.40) EGLN1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL4926820 0.90 EGLN1 (0.38) EGLN1MEN1KMT2ASMN1; SMN2DHODH
SCHEMBL4934946 0.90 SMN1; SMN2 (0.41) EGLN1MEN1KMT2ASMN1; SMN2DHODH
SCHEMBL5112232 0.89 KMT2A (0.39) EGLN1MEN1KMT2ASMN1; SMN2DHODH
SCHEMBL4931752 0.88 THRB (0.47) EGLN1MEN1KMT2ASMN1; SMN2DHODH
SCHEMBL5117974 0.86 EGLN1 (0.37) EGLN1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL4932995 0.86 THRB (0.39) EGLN1MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL5722542 0.86 MRGPRX4 (0.37) EGLN1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL4354703 0.85 THRA (0.42) EGLN1MEN1KMT2ASMN1; SMN2DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004251-A1 Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor KARO BIO AB (SE) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004251-A1 Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor TSHR, TRHR, THRA EGLN1 3052/4885MEN1 806/4885KMT2A 2895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.